Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 3INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 156Paclitaxel 154Bevacizumab 96Cyclophosphamide 61Gemcitabine 46olaparib 45Cisplatin 45Topotecan 44niraparib 40liposomal doxorubicin 40pembrolizumab 38Surveys and Questionnaires 33Filgrastim 31Hyperthermic Intraperitoneal Chemotherapy 29Docetaxel 27Taxes 25Blood Specimen Collection 24fludarabine 23Drug Therapy 23Cytoreduction Surgical Procedures 23Peripheral Blood Stem Cell Transplantation 21Etoposide 21Doxorubicin 21Magnetic Resonance Spectroscopy 20durvalumab 17Specimen Handling 17Albumin-Bound Paclitaxel 17Immunoglobulin G 15Disulfides 15Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasms × ipatasertib × Clear all
NCT04561817 2020-10-06

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡